Stockholm exchange. Sector: Healthcare. Industry: Health Information Services. Location Sweden, Gothenburg.

Surgical Science Sweden AB (publ) [SUS.STSweden

151.1USD1.7 (+1.13%)

• At close Thu Oct 06 2022

758,335,186 USD
MARKET CAP
315.111
PE
1.278
BETA (5y)
0.450
EPS

profit

1,062%

for 5 years

profit

551%

for 3 years

profit

69%

for 2 years

profit

28%

for 1 year

profit

-23%

for this year

About Surgical Science Sweden AB (publ)

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.

Medical training simulators for laparoscopy and endoscopy . Improve minimally invasive surgical skills quickly without putting patients at risk.

Surgical Science Sweden AB (publ)
https://www.surgicalscience.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.